 |
Continuous
Quality Improvement in Diabetes Services |
| |
Findings from DiabetesE - Fourth National Report.
104-page PDF (NHS Diabetes) |
| |
|
|
Doctors
deliver fresh warning over new QOF diabetes targets |
| |
Tighter blood glucose control targets for Type
2 diabetes in the QOF are not evidence-based and may do more harm
than good, two doctors are warning (Pulse) |
| |
|
|
Diabetes
drugs given 'too soon' |
| |
One in three people with type 2 diabetes are
given medication too soon, instead of being urged to eat better
and do more exercise, a study suggests (BBC) |
| |
|
|
Diabetic
retinopathy highly prevalent in UK South-Asian population |
| |
A primary-care based study has shown that Type
2 diabetes patients of South–Asian ethnicity living in the UK have a significantly higher prevalence of diabetic
retinopathy than their White–European counterparts (Medwire News) |
| |
|
|
Basal-bolus
therapy with insulin detemir using the 303 algorithm in the US
PREDICTIVE 303 trial |
| |
Adjustments of a once-daily detemir dose by
patients using the 303 Algorithm in a basalbolus setting is equally
effective in improving glycemic control in patients with type 2
diabetes compared with physician-directed basal dose adjustment
(PubMed) |
| |
|
|
FDA
says Takeda's alogliptin data is not "sufficient" |
| |
Takeda Pharmaceutical Co faces a delay in getting
alogliptin to market after US regulators said that they need more
data to evaluate the Japanese drugmaker’s experimental type 2 diabetes drug (PharmaTimes) |
| |
|
|
Color-Changing
Tattoos Could Be the Next BG Level Detector |
| |
Scientists at a Cambridge, Massachusetts, laboratory
who set out to develop a tattoo for tracking heart health may now
be on track for developing a tattoo for people with diabetes that
changes color as blood glucose levels rise and fall (Diabetes Health) |
| |
|
